OneMedNet Corp

OneMedNet Corporation announced that its iRWD Network has surpassed 90 million patient journeys and 270 million studies, with its healthcare partner network now exceeding 2,300 sites. This represents a 12.5% increase in patient journeys since April 2026 and a 30% expansion in provider sites in less than a year. The company highlighted this progress as direct execution against its strategic priorities for long-term value creation, meeting accelerating demand for Real-World Data and AI foundational models across various medical specialties.

OneMedNet Corp reported a net loss of $2.5 million for the first quarter of 2026, an increase from $1.9 million in the prior year, while total revenue decreased to $96,000. The company's cash balance of $233,000 as of March 31, 2026, is deemed inadequate to fund operations for the next twelve months, leading management to raise substantial doubt about its ability to continue as a going concern. OneMedNet plans to secure additional working capital through equity or debt offerings to support its operations.

OneMedNet Corp (ONMD) filed an Amendment No. 1 to its Form 10-K, providing previously omitted information regarding corporate governance, executive compensation, security ownership, and related party transactions. The amendment detailed 2025 compensation for named executive officers, including CEO Aaron Green ($1.11M), CFO Robert Golden ($0.50M), and CMO Dr. Jeffrey Yu ($0.54M). It also disclosed significant beneficial ownership by Dr. Thomas Kosasa (30.4%) and Dr. Jeffrey Yu (15.2%), along with related party investments and conversions of notes. Notably, the filing identified several delinquent Section 16(a) reports for directors and executive officers during 2025.

OneMedNet Corporation announced its iRWD Platform, built on Palantir Foundry, is now live and fully operational. This milestone provides searchable access to billions of records across 80 million patient journeys, significantly expanding the company's network to 251 million studies and enabling linkage to 47 million tokenized patients via Datavant. The company has already secured two new customers for the platform and anticipates converting a robust pipeline into high-margin, annual recurring revenue (ARR) subscriptions, positioning it for substantial revenue growth.

OneMedNet Corporation (ONMD) received a notice from Nasdaq on April 14, 2026, indicating non-compliance with the $1.00 minimum bid price requirement for continued listing. The company's common stock has traded below $1.00 for the past 30 consecutive business days. ONMD has 180 calendar days, until October 12, 2026, to regain compliance by having its stock close at or above $1.00 for at least ten consecutive business days. Failure to comply could lead to delisting, though an additional 180-day grace period may be available under certain conditions.